Summary
Twenty-one patients with solid tumors were treated with weekly 6-h intravenous infusions of dichloromethotrexate (DCM), with escalating doses every other week. Frequently observed toxicities included leukopenia, thrombocytopenia, and mucositis. Nausea, vomiting, diarrhea, and elevation of hepatic enzymes and bilirubin occurred less often. The toxicity of DCM was dose-dependent; the maximum tolerated dosage excalation plan was 400 mg/m2x2 weeks, 800 mg/m2x2 weeks, and then 1,200 mg/m2 weekly. Plasma concentrations of DCM were measured during 61 infusions and apparent half-lives determined. The plasma elimination of DCM appears to be similar to that of methotrexate. Three objective tumor responses seen in the seven hepatocellular carcinoma patients treated warrant further investigation.
Similar content being viewed by others
References
Adamson RH, Loo TL, Morris HP (1962) Metabolism of Cl36-dichloromethotrexate by transplantable liver tumors (27856). Proc Soc Exp Biol Med 111: 566
Band PR, Ross CA, Holland JF (1973) Comparison of two dose schedules of dichloromethotrexate (NSC 29630) in lung cancer. Cancer Chemother Rep 57: 79
Davidson JD, Oliverio VT (1965) The physiologic disposition of dichloromethotrexate-Cl36 in man. Clin Pharmacol Ther 6: 321
Donehower RC, Hande KR, Drake JC, Chabner BA (1979) Presence of 2,4-diamino-N10-methylpteroic acid after high-dose methotrexate. Clin Pharmacol Ther 26: 63
Fernbach B, Takahashi I, Ohnuma T, Holland JF (1979) Clinical and laboratory reevaluation of dichloromethotrexate. Recent Results Cancer Res 74: 56
Fox BW (1977) Collateral sensitivity between methylene dimethane sulfonate and halogenated methotrexate derivatives in the Yoshida sarcoma in vivo and in vitro. J Natl Cancer Inst 58: 955
Frei E, Spurr CL, Brindley CO, Selawry O, Holland JF, Rall DP, Wasserman LR, Hoogstraten B, Shnider BI, McIntyre OR, Matthews LB, Miller SP (1965) Clinical studies of dichloromethotrexate (NSC 29630). Clin Pharmacol Ther 6: 160
Friedkin M, Crawford E, Humphreys SR, Goldin A (1962) The association of increased dihydrofolate reductase with amethopterin resistance in mouse leukemia. Cancer Res 22: 600
Geddes EW, Falkson G (1970) Malignant hepatomas in the Bantu. Cancer 25: 1271
Goldin A, Humphreys SR, Venditti JM, Mantel N (1959) Prolongation of life span of mice with advanced leukemia (L1210) by treatment with halogenated derivatives of amethopterin. J Natl Cancer Inst 22: 811
McIntire KR, Vogel CL, Primack A, Waldmann TA, Kyalwazi SK (1976) Effect of surgical and chemotherapeutic treatment on alpha-fetoprotein levels in patients with hepatocellular carcinoma. Cancer 37: 677
The Merck Index (1968), 8th edn. Merck, Rahway, NJ, p 352
Misra DK, Adamson RH, Loo TL, Oliverio VT (1963) Inhibition of dihydrofolate reductase by dichloromethotrexate and its metabolite. Life Sci 6: 407
Ohnoshi T, Ohnuma T, Brown JC, Cohen S, Holland JF (1981) Clinical and laboratory studies of dichloromethotrexate (DCM) given every 6 hours. Proc Am Assoc Cancer Res/ASCO 22: 353
Oliverio VT, Davidson JD (1962) Physiological disposition of dichloromethotrexate-Cl36 in animals. J Pharmacol Exp Ther 137: 76
Olweny CLM, Katongole-Mbidde E, Bahendeka S, Otim D, Mugerwa J, Kyalwazi S (1980) Further experience in treating patients with hepatocellular carcinoma in Uganda. Cancer 46: 2717
Rosenberg SA, Chabner BA, Young RC, Seipp CA, Levine AS, Costa J, Hanson TA, Head GC, Simon RM (1979) Treatment of osteogenic sarcoma. I. Effect of high-dose methotrexate after amputation. Cancer Treat Rep 63: 739
Stoller RG, Hande KR, Jacobs SA, Rosenberg SA, Chabner BA (1977) Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med 297: 630
Takahashi I, Ohnuma T, Holland JF (1979) A comparison of the biological effects of dichloromethotrexate and methotrexate on human leukemic cells in culture. Cancer Res 39: 1264
Vogel CL, Adamson, RH, DeVita VT, Johns DG, Kyalwazi SK (1972) Preliminary clinical trials of dichloromethotrexate (NSC 29630) in hepatocellular carcinoma. Cancer Chemother Rep 56: 249
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tester, W.J., Donehower, R.C., Eddy, J.L. et al. Evaluation of weekly escalating doses of dichloromethotrexate in patients with hepatocellular carcinoma and other solid tumors. Cancer Chemother. Pharmacol. 8, 305–310 (1982). https://doi.org/10.1007/BF00254055
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00254055